FREMONT, Calif.--(BUSINESS WIRE)--Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Michael Mydra has joined the company as Senior Vice President of Reimbursement and Market Access.
“Michael has demonstrated the ability to achieve coding, coverage, and payment for multiple innovative medical technologies,” said Chris Gleason, President and CEO of Moximed. “He is a tremendous addition to the Moximed team. The experience he has gained from establishing five Category I CPT codes will be instrumental as we expand access of the MISHA® Knee System.”
Prior to joining Moximed, Michael served as the Senior Vice President of Reimbursement and Market Access at PainTEQ, Inc. Michael previously held reimbursement and market access leadership roles at multiple novel medical technology companies, including: Sanarus Medical, Vertos Medical, SI-BONE, Boston Scientific and Profound Medical.
“It is an honor to join the talented team at Moximed,” said Michael. “The clinical evidence supporting the MISHA Knee System is robust and will continue to grow. I am eager to help expand access to this disruptive technology as we look to transform the lives of millions of people affected by knee osteoarthritis.”
About The MISHA® Knee System
Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA.
Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.
Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.1
The MISHA Knee System is FDA cleared.
About Moximed
Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.
To learn more, visit www.moximed.com.
1. Morgan OJ, Hillstrom HJ, Ranawat A, Fragomen AT, Rozbruch SR, Hillstrom R. Effects of a Medial Knee Unloading Implant on Tibiofemoral Joint Mechanics During Walking. J Orthop Res. 2019;37(10):2149-2156. doi:10.1002/jor.24379.
